Screener / SEC EDGAR /CIK 0001388658 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

iRhythm Holdings, Inc. IRTC

Compare with peers Embed
New in the 10-K 10 paragraphs with nothing like them in the 10-K filed Feb 20, 2025 New in the 10-Q 45 paragraphs not in the 10-Q filed Aug 6, 2026 10-Q against the 10-K 121 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 20, 2025. A box jumps to the paragraph as filed, below.

10 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

10 paragraphs in Risk Factors of the 10-K filed Feb 19, 2026 with nothing like them in the 10-K filed Feb 20, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

requirements, coverage criteria, procedures, or expectations. We also bill insured patients for co-payments, co-insurance, and deductible amounts, as well as bill self-pay patients directly.

Read in the 10-K

the filing of reports may increase regulator and public scrutiny, especially given that these reports are typically publicly available information in most jurisdictions, including the United States, which could harm our business.

Read in the 10-K

•compliance risks under the EU and UK General Data Protection Regulation (collectively, the “GDPR”), including restrictions on the cross-border transfers of personal data, as applicable;

Read in the 10-K

We also regularly evaluate a variety of other potential strategic transactions, including equity and other investments and strategic alliances. Equity and other investments and strategic alliances pose additional risks, as we could share ownership and, in some cases, management responsibilities with one or more other parties whose objectives may diverge from ours over time; who may not have the same priorities, strategies, or resources as we do; or whose interpretation of applicable policies may differ from our own.

Read in the 10-K

Healthcare laws and regulations, and interpretations of the same, change frequently and may change significantly in the future. We may not be able to adapt our operations to address every new regulation or interpretation, and new regulations or interpretations may adversely affect our business. For example, FDA has taken novel steps in recent years to regulate MCT devices—including Zio AT—through administrative actions including development of Product Code QYX and assignment of that Product Code to certain devices already on the market, and also to applicants seeking 510(k) clearance for devices used in MCT monitoring services. FDA’s inclusion in the Product Code’s “Definition” of “Outpatient Cardiac Telemetry” devices certain activities in the purview of IDTFs and other monitoring locations presents the potential for these activities to be viewed as a component of the device subject to direct FDA oversight. It remains unclear how FDA will continue to interpret and enforce the device requirements for devices that FDA assigns to Product Code QYX.

There also remains general uncertainty regarding future government activities, including enforcement policies. For example, DOJ disbanded the CBP, which was responsible for enforcement of the FD&C Act. Following dissolution of the CPB, on September 25, 2025, DOJ announced a restructuring under which the Civil Division’s litigation work would be consolidated into a new Enforcement & Affirmative Litigation Branch, and the Health and Safety Unit housed within the Fraud Section of DOJ’s Criminal Division is now charged with criminal enforcement of the FD&C Act. The current presidential administration could also issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new diagnostic products or services. Alternatively, state governments may attempt to address perceived gaps in regulation or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations, policies or guidance as a result of the current presidential administration or state regulatory responses, there could be a material adverse effect on us and our business. We also cannot assure that a review of our business by courts or regulatory authorities would not result in a determination that adversely affects our revenue and operating results.

Read in the 10-K
Show the other 3

expansion), and rolling back regulatory initiatives adopted under the previous administration. We cannot predict whether industry initiatives to seek tariff carve-outs for devices or other life sciences goods and products will be successful.

Read in the 10-K

As a public company, we are subject to certain reporting requirements, including those under the Sarbanes-Oxley Act, which requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In order to maintain and improve the effectiveness of our internal controls and disclosure controls and procedures, we have expended, and anticipate that we will continue to expend, significant resources, including accounting related costs and significant management oversight.

Maintaining effective internal control and disclosure controls and procedures requires ongoing attention and resources. We continue to seek improvements to enhance our control environment and to strengthen our internal controls to provide reasonable assurance that our financial statements continue to be fairly stated in all material respects.

Read in the 10-K

In addition, the BIOSECURE Act was signed into law in December 2025 as part of the National Defense Authorization Act restricting U.S. federal contracts and funding for companies using biotech equipment or services from "biotechnology companies of concern" ("BCCs"), to curb national security risks. A phased rollout includes publishing lists of BCCs, issuing guidance, and revising Federal Acquisition Regulations with full prohibitions taking effect over a period of years. Compliance with this law will require us to perform additional supply chain due diligence and potentially change supplier sources if we wish to do business with the U.S. government such as the Veterans Administration. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 5, 2026 that were not in the one before

New in the latest 10-Q

45 paragraphs in the 10-Q filed Nov 5, 2026 with nothing like them in the 10-Q filed Aug 6, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

10-Q

• the anticipated benefits, impacts and integration costs and risks of our acquisition of Vital Connect, Inc., a Delaware corporation, and the time to achieve any such benefits;

Read in the 10-Q

• our expectations regarding our liquidity and cash flow and our ability to service our indebtedness, and our ability to comply with covenants applicable to our senior secured revolving credit facility;

Read in the 10-Q

Financial statements and notes

On October 5, 2026, the Company completed the previously announced acquisition of Vital Connect, Inc., a Delaware corporation (“VitalConnect”), with VitalConnect becoming an indirect wholly-owned subsidiary of the Company. The Company paid approximately $ 237.5 million in cash, subject to customary final adjustments, and will issue up to 423,334 shares of common stock in connection with the closing of the VitalConnect acquisition upon successful transmission of evidence of ownership by former VitalConnect shareholders and other customary documentation. In August 2026, the Company provided VitalConnect with $ 10.0 million of interim working capital financing to fund its normal course of operations and certain specified expenses as both parties worked toward closing the acquisition.

Read in the 10-Q

The acquisition of VitalConnect expands the Company’s capabilities across ambulatory cardiac monitoring, creating a broader portfolio to serve diverse clinical needs. The Company also anticipates that the combination may create commercial acceleration opportunities by leveraging the Company’s scale, customer relationships, and go-to-market capabilities.

Read in the 10-Q

Due to the limited time since the acquisition date and availability of information, the preliminary acquisition valuation for the business combination is incomplete. As a result, the Company is unable to provide the amounts recognized as of the acquisition date for the major classes of assets acquired and liabilities assumed, including the information required for valuation of intangible assets and goodwill. The Company will include such disclosures in its Annual Report on Form 10-K for the year ending December 31, 2026.

Read in the 10-Q
Show the other 40

On November 3, 2026, the Company. as guarantor, its wholly-owned subsidiary, iRhythm Technologies, as borrower, and certain of the Company’s other subsidiaries, as guarantors, entered into a senior secured credit agreement (the "Credit Agreement") with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto, which provides for a $ 300.0 million senior secured revolving credit facility with sublimits of $ 10.0 million in the aggregate for loans and letters of credit denominated in foreign currencies, $ 30.0 million for the issuance of letters of credit and $ 10.0 million for swingline loans (the "Revolving Credit Facility"). The Revolving Credit Facility matures on November 3, 2031, subject to an earlier springing maturity 91 days before the scheduled maturity of certain unsecured, subordinated or junior-lien indebtedness (including the 2029 Notes) if certain conditions exist. Any borrowings under the Revolving Credit Facility bear interest, at the borrower’s option, at (i) the Term SOFR rate (or, for borrowings denominated in certain foreign currencies, the applicable benchmark rate for such currency) plus a spread of 2.00 % to 2.75 % or (ii) an alternate base rate plus a spread of 1.00 % to 1.75 %, in each case based on the Company’s senior secured net leverage ratio. The Company is also obligated to pay an ongoing commitment fee on undrawn amounts. Funds borrowed under the Revolving Credit Facility may be used for general corporate purposes. No amounts were borrowed under the Revolving Credit Facility at closing. See Part II, Item 5 of this Quarterly Report on Form 10-Q for additional information regarding the Revolving Credit Facility including details of the springing maturity feature.

Read in the 10-Q

On October 5, 2026, we completed the acquisition of Vital Connect, Inc., a Delaware corporation ("VitalConnect"), with VitalConnect becoming our indirect wholly-owned subsidiary. VitalConnect is a leader in wearable biosensor technology and is expanding its presence in ambulatory cardiac monitoring. VitalConnect's platform combines the FDA-cleared VitalPatch along with proprietary AI-powered algorithms, and cloud-based workflow solutions to enable patient monitoring. VitalConnect's platform is designed to provide continuous, actionable patient data through an easy-to-use experience for patients and healthcare providers in the remote and inpatient settings. The acquisition of VitalConnect expands our capabilities across ambulatory cardiac monitoring, creating a broader portfolio to serve diverse clinical needs. We also anticipate that the combination may create commercial acceleration opportunities by leveraging our scale, customer relationships, and go-to-market capabilities.

Read in the 10-Q

The following table presents iRhythm revenue by payor type as a percentage of revenue:

Read in the 10-Q

2 Business transformation costs include $6.0 million associated with the VitalConnect acquisition for the three and nine months ended September 30, 2026.

Read in the 10-Q

On October 5, 2026, we completed the previously announced acquisition of VitalConnect. As a result of this, VitalConnect became our indirect wholly-owned subsidiary. We paid approximately $237.5 million in cash, subject to customary final adjustments, and will issue up to 423,334 shares of common stock in connection with the closing of the VitalConnect acquisition. In August 2026, we provided VitalConnect with $10.0 million of interim working capital financing to fund its normal course of operations and certain specified expenses as both parties worked toward closing the acquisition.

Read in the 10-Q

On November 3, 2026, we, as guarantor, our wholly-owned subsidiary, iRhythm Technologies, as borrower, and certain of our other subsidiaries, as guarantors, entered into entered into a senior secured credit agreement (the "Credit Agreement") with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto, which provides for a $300 million senior secured revolving credit facility with sublimits of $10.0 million in the aggregate for loans and letters of credit denominated in foreign currencies, $30.0 million for the issuance of letters of credit and $10.0 million for swingline loans (the "Revolving Credit Facility"). The Revolving Credit Facility matures on November 3, 2031, subject to an earlier springing maturity 91 days before the scheduled maturity of certain unsecured, subordinated or junior-lien indebtedness (including the 2029 Notes) if certain conditions exist. Any borrowings under the Revolving Credit Facility bear interest, at the borrower’s option, at (i) the Term SOFR rate (or, for borrowings denominated in certain foreign currencies, the applicable benchmark rate for such currency) plus a spread of 2.00% to 2.75% or (ii) an alternate base rate plus a spread of 1.00% to 1.75%, in each case based on our senior secured net leverage ratio. We are also obligated to pay an ongoing commitment fee on undrawn amounts. Funds borrowed under the Revolving Credit Facility may be used for general corporate purposes. No amounts were borrowed under the Revolving Credit Facility at closing. See Part II, Item 5 of this Quarterly Report on Form 10-Q for additional information regarding the Revolving Credit Facility including details of the springing maturity feature.

Read in the 10-Q

Risk Factors

• We may fail to realize the anticipated benefits of our acquisition of VitalConnect or those benefits may take longer to realize than expected, and we may encounter significant integration difficulties in addition to the legal and compliance risks present for companies such as VitalConnect, many of which are comparable to those otherwise applicable to its parent iRhythm Technologies, Inc. ("iRhythm Technologies"), and some of which may present different, additional, or elevated risks.

Read in the 10-Q

We may fail to realize the anticipated benefits of our acquisition of VitalConnect or those benefits may take longer to realize than expected, and we may encounter significant integration difficulties in addition to the legal and compliance risks present for companies such as VitalConnect, many of which are comparable to those otherwise applicable to iRhythm, and some of which may present different, additional, or elevated risks.

Read in the 10-Q

On October 5, 2026, we completed the acquisition of Vital Connect, which became our indirect wholly-owned subsidiary. The success of the acquisition will depend, in part, on successfully combining our and VitalConnect’s business practices and operations. We expect the integration process to be complex, costly and time-consuming and to continue to require significant management attention and resources. Additionally, integration costs and investments in the VitalConnect product portfolio may exceed our expectations. The expected benefits may not be achieved within the anticipated time frame, or at all. The VitalConnect product portfolio may also not have the commercial potential we envision. We may not be able to integrate the two businesses successfully, and we could assume unknown or contingent costs, delays, or liabilities across a wide range of risk areas.

Read in the 10-Q

For example, the regulatory, quality, clinical operations, and billing and reimbursement functions of iRhythm’s business and VitalConnect’s business are highly complex and technical, and we may encounter challenges in integrating these aspects of our business. The integration process could divert our management’s attention, disrupt or interrupt our ongoing business or cause our business to lose momentum or result in inconsistencies in standards, controls, procedures and policies. These difficulties could adversely affect our ability to maintain relationships with third parties or achieve the anticipated benefits of the acquisition or could otherwise adversely affect our business and financial results.

Read in the 10-Q

In addition to the potential challenges and risks associated with its integration, VitalConnect is subject to the risks of a device developer, manufacturer, supplier, and marketing authorization holder as well as a Medicare-enrolled IDTF that provides and bills for certain diagnostic medical procedures. Refer to the other Risk Factors in this Item 1A. Risk Factors, including but not limited to Risks Related to Our Industry, Business and Operations; Risks Related to Healthcare Regulatory Matters, and Risks Related to Privacy and Security. The risks related to the FDA and healthcare and privacy legal and regulatory landscape described for the iRhythm ACM System and historic iRhythm and Zio devices and services also generally apply to VitalConnect products and services.

Read in the 10-Q

Further, certain aspects of Vital Connect’s business may present different, additional, or elevated risks as compared to iRhythm’s business prior to the acquisition. For example, VitalConnect’s products include the multi-modal VitalConnect Solution, which can support different types of remote cardiac monitoring services, including mobile cardiac telemetry (“MCT”), long-term continuous monitoring, cardiac event monitoring, and traditional, short-term Holter monitoring services. Marketing multi-modal devices may subject VitalConnect, and now iRhythm, to a high degree of scrutiny for compliance with applicable laws and regulations, as highlighted by a 2017 settlement of an enforcement action brought against AMI Monitoring Inc., et al., as well as a 2023 settlement of an enforcement action brought against BioTelemetry, Inc., both of which resolved allegations related to the marketing of multi-modal devices and the design of online enrollment portals related to those devices. As another example, VitalConnect supplies certain devices to third parties outside of their use in VitalConnect’s own service offerings, and potential FDA compliance and enforcement risks and contractual risks may be present in these third-party relationships beyond those present in iRhythm’s business prior to the acquisition.

Read in the 10-Q

We continue to devote time and resources into commercializing the sleep apnea screening and diagnostics market, which carries unique regulatory requirements, as well as coding and reimbursement policies that remain in flux, and remains an ongoing area of focus for government enforcement.

Read in the 10-Q

expenses, including notification, mitigation, and remediation costs, disrupt our operations and the services we provide to our clients, or damage our reputation, any of which could adversely affect our profitability, revenue, and competitive position.

Read in the 10-Q

Increasing our financial leverage could affect our operations and profitability.

Read in the 10-Q

We are party to the Credit Agreement, dated as of November 3, 2026, among iRhythm Holdings, Inc., iRhythm Technologies, as borrower, the other loan parties party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, which provides for the Credit Facility, a $300.0 million senior secured revolving credit facility. The Credit Facility matures on November 3, 2031, subject to an earlier springing maturity if, 91 days before the scheduled maturity of certain of our other indebtedness, including the 2029 Notes, the amount of such indebtedness then outstanding exceeds a specified threshold and the amount of our liquidity (defined as unrestricted cash and cash equivalents held in the U.S. plus amounts available to borrow under the Credit Facility) is not greater than 150% of the principal amount of such indebtedness. Based on the principal amount of the 2029 Notes currently outstanding, unless, before June 1, 2029, we refinance, repurchase or otherwise reduce the outstanding 2029 Notes below the applicable threshold or, unless we satisfy the minimum liquidity requirement on that date, the Credit Facility would mature on June 1, 2029, the business day preceding the date that is 91 days before the September 1, 2029 maturity of the 2029 Notes. As of the date of this Quarterly Report on Form 10-Q, we had no borrowings outstanding under the Credit Facility.

Read in the 10-Q

Our leverage ratio, combined with our other financial obligations and contractual commitments, may affect our ability to obtain additional capital resources as well as our operations in several ways, including:

Read in the 10-Q

• the possibility that credit may be available to us on less attractive economic terms and subject to less attractive legal covenants;

Read in the 10-Q

• the potential for higher levels of interest expense to service or maintain our outstanding debt, including because borrowings under the Credit Facility bear interest at a variable rate;

Read in the 10-Q

• the possibility that we will be required to incur additional debt in the future to repay our existing indebtedness when it comes due;

Read in the 10-Q

• the possibility that our level of indebtedness makes us more vulnerable to adverse changes in general U.S. and worldwide economic, industry, and competitive conditions and adverse changes in government regulation;

Read in the 10-Q

• the possibility that an acquisition of our company may be less attractive or more difficult.

Read in the 10-Q

Any of these factors could harm our business, results of operations, and financial condition. While we believe we will have the ability to service our obligations under the Credit Agreement and obtain additional financing in the future if and when needed, that will depend upon our results of operations and financial position at the time, the then-current state of the credit and financial markets, and other factors that may be beyond our control. Therefore, we cannot give assurances that sufficient credit will be available on terms that we consider attractive, or at all, if and when necessary or beneficial to us.

Read in the 10-Q

Failure to comply with covenants in the Credit Agreement could result in our inability to borrow additional funds and adversely impact our business.

Read in the 10-Q

The Credit Agreement imposes numerous financial and other restrictive covenants on our operations, including covenants limiting our ability to incur additional indebtedness and liens, make investments and acquisitions, dispose of assets, and pay dividends or repurchase our stock, in each case subject to certain exceptions, and covenants requiring regulatory compliance and reporting of certain adverse regulatory events. The Credit Agreement also requires that we maintain a maximum senior secured net leverage ratio and a minimum interest coverage ratio, each tested on a quarterly basis. Our ability to comply with these and other covenants is dependent upon several factors, some of which are beyond our control. As of the date of this Quarterly Report on Form 10-Q, we were in material compliance with the covenants then applicable under the Credit Agreement. If we violate these or any other covenants under the Credit Agreement, fail to make payments in connection therewith, or experience certain other events, including a default under our other material indebtedness or a change of control, an event of default could occur, which would give the lenders the right to terminate their commitments to provide additional loans and declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. In addition, the lenders would have the right to proceed against substantially all of our assets pledged as collateral under the Credit Agreement, which could materially impair our ability to continue operations. Our ability to borrow under the Credit Facility is also subject to the absence of any default and the accuracy of our representations and warranties at the time of each borrowing. Any of the foregoing may limit our ability to borrow additional funds and pursue other business opportunities or strategies that we would otherwise consider to be in our best interests.

Read in the 10-Q

Share sales and buybacks

None, except as previously reported on a Current Report on Form 8-K filed with the SEC on August 6, 2026.

Read in the 10-Q

Other information

The following information is included in this Quarterly Report on Form 10-Q in lieu of filing a Current Report on Form 8-K reporting the information required to be disclosed under Items 1.01 and 2.03 of Form 8-K.

Read in the 10-Q

Legal proceedings

On November 3, 2026, iRhythm Holdings, Inc. (the “Company”), as guarantor, its subsidiary iRhythm Technologies, Inc. (the “Borrower”), as borrower, and certain of the Company’s other subsidiaries (collectively, the “Subsidiary Guarantors”), as guarantors party thereto, entered into a senior secured credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders and issuing banks party thereto. The Credit Agreement provides for a $300.0 million revolving credit facility, with sublimits of $10.0 million in the aggregate for loans and letters of credit denominated in foreign currencies, $30.0 million for the issuance of letters of credit and $10.0 million for swingline loans (the “Revolving Credit Facility”). The Revolving Credit Facility matures on the fifth anniversary of the effective date of the Credit Agreement, subject to an earlier springing maturity 91 days before the scheduled maturity of certain unsecured, subordinated or junior-lien indebtedness (including the Borrower’s 1.50% Convertible Senior Notes due 2029) if the aggregate principal amount of all such indebtedness maturing within that 91-day period exceeds 100% of Consolidated EBITDA (generally, consolidated net income or loss before interest, taxes, depreciation and amortization, subject to certain adjustments for non-cash items, non-recurring items and other customary adjustments) for the most recent four-fiscal-quarter period for which financial statements have been delivered. The springing maturity is subject to an exception where liquidity (defined as unrestricted cash and cash equivalents held in the U.S. plus amounts available under the Revolving Credit Facility) on the applicable springing maturity date is greater than 150% of the aggregate outstanding principal amount of the applicable earlier-maturing indebtedness.

Read in the 10-Q

The loans under the Revolving Credit Facility may be denominated in U.S. dollars, euros, sterling, Australian dollars, Singapore dollars, Swiss francs and Japanese yen. Loans incurred under the Revolving Credit Facility bear interest at a rate equal to (i) for loans denominated in U.S. dollars, at the Borrower’s election, the Term SOFR Rate (a forward-looking term rate based on the secured overnight financing rate, subject to a 0% floor) or the Alternate Base Rate (generally, the highest of the U.S. prime rate published by The Wall Street Journal, 0.50% above the greater of the federal funds effective rate and the overnight bank funding rate, and the one-month Term SOFR Rate plus 1.00%, subject to a 1.00% floor), except that swingline loans use the Alternate Base Rate, and (ii) for loans denominated in foreign currencies, EURIBOR, TIBOR or BBSY for euros, Japanese yen or Australian dollars, respectively, or daily simple SONIA, SORA or SARON for sterling, Singapore dollars or Swiss francs, respectively, subject to applicable reserve adjustments and a 0% floor, in the case of each of the foregoing clauses (i) and (ii), plus an applicable margin based on the Company’s Senior Secured Net Leverage Ratio (generally, indebtedness of the Company and its subsidiaries that is secured by a lien on their assets, excluding payment-subordinated or junior-lien indebtedness and net of unrestricted cash and cash equivalents held in the U.S. in excess of $100.0 million, divided by Consolidated EBITDA for the most recent four-fiscal-quarter period). The applicable margin ranges from 1.00% to 1.75% for loans bearing interest at the Alternate Base Rate and 2.00% to 2.75% for term benchmark or overnight reference rate loans.

Read in the 10-Q

The Credit Agreement provides for (i) commitment fees on the unused commitments under the Revolving Credit Facility (excluding swingline loans from usage for this purpose), ranging from 0.25% to 0.35% per annum based on the Company’s Senior Secured Net Leverage Ratio, and (ii) an incremental accordion feature permitting additional revolving commitments and/or incremental term loans, with capacity shared with other notes or loans incurred in lieu of such incremental facilities, of up to the sum of (x) the greater of (A) $140.0 million and (B) 100% of Consolidated EBITDA, less prior utilization of that component that remains outstanding or effective, (y) qualifying voluntary prepayments, repurchases or redemptions of incremental indebtedness and permanent reductions of revolving commitments, and (z) additional amounts subject to a Total Secured Net Leverage Ratio (generally, total secured indebtedness of the Company and its subsidiaries, including junior-lien indebtedness, net of unrestricted cash and cash equivalents held in the U.S. in excess of $100.0 million, divided by Consolidated EBITDA for the most recent four-fiscal-quarter period) not exceeding 2.75 to 1.00 on a pro forma, fully drawn basis, excluding the proceeds of the additional indebtedness from cash netting, in each case subject to obtaining lender commitments and satisfying customary conditions.

Read in the 10-Q

No amounts were borrowed under the Revolving Credit Facility at closing. Proceeds of borrowings under the Revolving Credit Facility may be used for general corporate purposes of the Company and its subsidiaries.

Read in the 10-Q

The Credit Agreement requires the Company to maintain (i) a Senior Secured Net Leverage Ratio not exceeding 3.00 to 1.00, subject to a step-up, at the Company’s election, to 3.50 to 1.00 for four consecutive fiscal quarters commencing with the fiscal quarter in which the Company completes certain permitted acquisitions or similar investments having consideration that is equal to or greater than $50.0 million, and (ii) an Interest Coverage Ratio (generally, Consolidated EBITDA divided by consolidated cash interest expense of the Company and its subsidiaries, including the interest component of capitalized leases, for the same four-fiscal-quarter period) of at least 3.00 to 1.00, in each case tested quarterly commencing with the fiscal quarter ending December 31, 2026.

Read in the 10-Q

The Revolving Credit Facility is guaranteed by the Company and the Subsidiary Guarantors and secured by substantially all of the assets of the Company, the Borrower and the Subsidiary Guarantors, subject to customary exclusions and limitations set forth in the Credit Agreement and the related loan documents. The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including negative covenants that, subject to the exceptions set forth in the Credit Agreement, limit the ability of the Company and its subsidiaries to incur additional debt, incur or permit liens on assets, make investments, engage in asset sales and pay dividends and make distributions. The Credit Agreement permits the Company, among other things, to repurchase shares of its common stock without limitation as to amount, subject to compliance with specified leverage ratio tests and the absence of a default. Whether or not those leverage ratio tests are satisfied, the Credit Agreement also permits the Company to repurchase shares of its common stock in an aggregate amount of up to $30.0 million per fiscal year (with unused amounts carried forward to the next fiscal year).

Read in the 10-Q

Obligations under the Credit Agreement may be accelerated upon the occurrence of certain customary events of default (subject, in appropriate cases, to grace periods set forth in the Credit Agreement), including the following: nonpayment of principal, interest or fees; breach of the affirmative, negative or financial covenants; breach of the representations or warranties in any material respect; events of default with respect to other material indebtedness; bankruptcy or insolvency; material judgments entered against the Company or any of its subsidiaries that satisfy the applicable enforcement or unstayed-period conditions under the Credit Agreement; invalidity or unenforceability of the security documents and guarantees associated with the Credit Agreement; and a change of control.

Read in the 10-Q

Certain of the lenders and agents under the Credit Agreement and their respective affiliates have provided, and may in the future provide, commercial banking, investment banking and other financial services to the Company and its affiliates, for which they have received, and may in the future receive, customary fees and expenses.

Read in the 10-Q

The foregoing description of the Credit Agreement does not purport to be complete. The Credit Agreement will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2026.

Read in the 10-Q

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

Read in the 10-Q

The disclosure set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

Read in the 10-Q

Item 6

† Schedules or similar attachments have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished to the SEC upon request.

Read in the 10-Q

‡ Confidential treatment has been requested for portions of this exhibit, which have been omitted from this filing (indicated by [***]) pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of the omitted portions to the SEC upon request.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 5, 2026 against Item 1A of the 10-K filed Feb 19, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
• We may fail to realize the anticipated benefits of our acquisition of VitalConnect or those benefits may take longer to realize than expected, and we may encounter significant integration difficulties in addition to the legal and compliance risks present for companies such as VitalConnect, many of which are comparable to those otherwise applicable to its parent iRhythm Technologies, Inc. ("iRhythm Technologies"), and some of which may present different, additional, or elevated risks.

Read it in the 10-Q at sec.gov

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
We have experienced significant changes in our executive leadership in recent years and we may experience further changes in executive leadership in the future.

Read it in the 10-Q at sec.gov

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
We may fail to realize the anticipated benefits of our acquisition of VitalConnect or those benefits may take longer to realize than expected, and we may encounter significant integration difficulties in addition to the legal and compliance risks present for companies such as VitalConnect, many of which are comparable to those otherwise applicable to iRhythm, and some of which may present different, additional, or elevated risks.

Read it in the 10-Q at sec.gov

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
On October 5, 2026, we completed the acquisition of Vital Connect, which became our indirect wholly-owned subsidiary. The success of the acquisition will depend, in part, on successfully combining our and VitalConnect’s business practices and operations. We expect the integration process to be complex, costly and time-consuming and to continue to require significant management attention and resources. Additionally, integration costs and investments in the VitalConnect product portfolio may exceed our expectations. The expected benefits may not be achieved within the anticipated time frame, or at all. The VitalConnect product portfolio may also not have the commercial potential we envision. We may not be able to integrate the two businesses successfully, and we could assume unknown or contingent costs, delays, or liabilities across a wide range of risk areas.

Read it in the 10-Q at sec.gov

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
For example, the regulatory, quality, clinical operations, and billing and reimbursement functions of iRhythm’s business and VitalConnect’s business are highly complex and technical, and we may encounter challenges in integrating these aspects of our business. The integration process could divert our management’s attention, disrupt or interrupt our ongoing business or cause our business to lose momentum or result in inconsistencies in standards, controls, procedures and policies. These difficulties could adversely affect our ability to maintain relationships with third parties or achieve the anticipated benefits of the acquisition or could otherwise adversely affect our business and financial results.

Read it in the 10-Q at sec.gov

Show the other 20
Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
In addition to the potential challenges and risks associated with its integration, VitalConnect is subject to the risks of a device developer, manufacturer, supplier, and marketing authorization holder as well as a Medicare-enrolled IDTF that provides and bills for certain diagnostic medical procedures. Refer to the other Risk Factors in this Item 1A. Risk Factors, including but not limited to Risks Related to Our Industry, Business and Operations; Risks Related to Healthcare Regulatory Matters, and Risks Related to Privacy and Security. The risks related to the FDA and healthcare and privacy legal and regulatory landscape described for the iRhythm ACM System and historic iRhythm and Zio devices and services also generally apply to VitalConnect products and services.

Read it in the 10-Q at sec.gov

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
Further, certain aspects of Vital Connect’s business may present different, additional, or elevated risks as compared to iRhythm’s business prior to the acquisition. For example, VitalConnect’s products include the multi-modal VitalConnect Solution, which can support different types of remote cardiac monitoring services, including mobile cardiac telemetry (“MCT”), long-term continuous monitoring, cardiac event monitoring, and traditional, short-term Holter monitoring services. Marketing multi-modal devices may subject VitalConnect, and now iRhythm, to a high degree of scrutiny for compliance with applicable laws and regulations, as highlighted by a 2017 settlement of an enforcement action brought against AMI Monitoring Inc., et al., as well as a 2023 settlement of an enforcement action brought against BioTelemetry, Inc., both of which resolved allegations related to the marketing of multi-modal devices and the design of online enrollment portals related to those devices. As another example, VitalConnect supplies certain devices to third parties outside of their use in VitalConnect’s own service offerings, and potential FDA compliance and enforcement risks and contractual risks may be present in these third-party relationships beyond those present in iRhythm’s business prior to the acquisition.

Read it in the 10-Q at sec.gov

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
We continue to devote time and resources into commercializing the sleep apnea screening and diagnostics market, which carries unique regulatory requirements, as well as coding and reimbursement policies that remain in flux, and remains an ongoing area of focus for government enforcement.

Read it in the 10-Q at sec.gov

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
For example, during the first quarter of 2024, we experienced a temporary delay in the billing of our contracted and non-contracted payer customers, performed by our third-party claims processing vendor. The delay was due to a cybersecurity incident experienced by Change Healthcare, a division of UnitedHealth Group, with whom one of our third-party vendors engages for services relating to billing and collections. The delay in billing resulted in a temporary delay in our cash collections.

Read it in the 10-Q at sec.gov

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
Further, in June 2026, as previously disclosed on a Current Report on Form 8-K filed with the SEC on June 15, 2026, a threat actor improperly obtained certain sensitive information of ours maintained on certain third-party-hosted business applications. We continue to face risks relating to this incident, including possible harm to our reputation and customer relationships, and ongoing litigation, as well as regulatory scrutiny. While, based on our investigation, the incident has not impacted our products, clinical or medical device systems, patient safety, manufacturing and distribution operations, financial reporting systems, or our ability to meet patient needs, we may in the future discover other impacts or new related events that could affect our business, operating results, and financial condition.

Read it in the 10-Q at sec.gov

Added10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
expenses, including notification, mitigation, and remediation costs, disrupt our operations and the services we provide to our clients, or damage our reputation, any of which could adversely affect our profitability, revenue, and competitive position.

Read it in the 10-Q at sec.gov

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
In addition, we may be unable The Credit Agreement limits our ability to repurchase the 2029 Notes upon a fundamental change when required by the holders or repay prior to maturity any accelerated amounts due under the 2029 Notes upon an event of default or redeem the 2029 Notes or pay cash in excess of principal upon conversion of the 2029 Notes, Notes in certain circumstances, and our future debt may contain limitations on our ability to pay cash upon conversion, repurchase or repayment of the 2029 Notes.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
Failure to maintain full compliance with the requirements of FDA's QMSR, QSR, now referred to as the Quality Management System Regulation or "QMSR", the EU MDR, Medical Device Regulation (formally Regulation (EU) 2017/745 or "EU MDR"), the UK MDR, Medical Devices Regulations (formally the Japanese QMS Medical Devices Regulations 2002 (SI 2002/618) or "UK MDR"), Japan's Quality Management System Ordinance ("Japanese QMS") and the Swiss MedDO Medical Devices Ordinance ("MedDO") could result in similar disruptions in these markets.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
AI solutions may be controversial because of their impact or perceived impact on human rights, privacy, employment, or other social, economic, or political issues, or if we are unable to develop effective internal policies and frameworks relating to the responsible development and use of AI models and systems, we may experience brand, reputational, and/or competitive harm, or could face legal liability. issues.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
Reimbursement by Medicare is highly regulated ("VitalConnect)", and subject to change, and our failure to comply with applicable regulations, including regulations not designed for remote diagnostic tests like our iRhythm Services, sleep testing services (collectively, the "Company Offerings"), could prevent us from receiving reimbursement under the Medicare program and some commercial payors, subject us to penalties, and adversely affect our reputation, business, and results of operations.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
Any resulting unauthorized access, disclosure, or other loss of information by us or one of our service providers could result in legal claims or proceedings, and liability under laws that protect the privacy of personal data and regulatory penalties, increase in operating expenses, incurrence of expenses, including notification, mitigation, and remediation costs, disrupt our operations and the services we provide to our clients, or damage our reputation, any of which could adversely affect our profitability, revenue, and competitive position.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
Improper billing activities related to HST product or service offerings have been an area of significant government scrutiny in recent years. years as evidenced by recent settlements under the False Claims Act involving alleged lack of medical necessity and billing for more sessions of testing than warranted to effectively diagnose obstructive sleep apnea.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
An increase in the reporting of events associated with the use of our products and services from us or others and any delays to the filing of reports may increase regulator and public scrutiny, especially given that these reports are typically publicly available information in most jurisdictions, including the United States, which could harm our business.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
We could incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations operations, cash flows, and financial condition in any particular period. period, including as a result of the timing and amount of settlement payments and the availability and timing of any related insurance recoveries.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
For example, as discussed further in Note 8, 7, Commitments and Contingencies, to the Consolidated Financial Statements, our unaudited condensed consolidated financial statements included herein, we recently settled a putative securities class action lawsuit was filed against iRhythm Technologies and certain of its then current and former officer officers alleging violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder, and we recently settled two patent lawsuits have that had been filed against iRhythm Technologies by companies affiliated with Baxter International. Baxter.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
In addition, we may be unable to repurchase the 2029 Notes upon a fundamental change when required by the holders or holders, repay prior to maturity any accelerated amounts due under the 2029 Notes upon an event of default or default, redeem the 2029 Notes Notes, or pay cash upon conversion of the 2029 Notes, and our future debt may contain limitations on our ability to pay cash upon conversion, repurchase or repayment of the 2029 Notes.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
We continue to devote time and resources into exploring developing the sleep apnea screening and diagnostics market. market, which carries unique regulatory requirements, as well as coding and reimbursement policies that remain in flux, and remains an area of focus for government enforcement.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 5, 2026 vs 10-K Feb 19, 2026
AI solutions may be controversial because of their impact or perceived impact on human rights, privacy, employment, or other social, economic, or political issues, or if If we are unable to develop effective internal policies and frameworks relating to the responsible development and use of AI models and systems, we may experience brand, reputational, and/or competitive harm, or could face legal liability.

Read it in the 10-Q at sec.govThe 10-K sentence

The first 25 of 121 are shown (at most 12 of each type).

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 19, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 20, 2025

irhythm services ×90irhythm acm ×38acm systems ×29acm system ×9irhythm technologies ×6code qyx ×5proposed lcds ×4swiss meddo ×3current presidential ×3risk adjustment ×2coverage determinations ×2ambulatory cardiac ×2device requirements ×2product codes ×2telemetry devices ×2increased audit ×2
Where each one is used
  • irhythm services: Reimbursement by Medicare is highly regulated and subject to change, and our failure to comply with applicable regulations, including regulations not designed for remote diagnostic tests like our iRhythm Services, could prevent us from receiving reimbursement under the Medicare program and some commercial payors,...
  • irhythm acm: Because remote cardiac monitoring technology, including the iRhythm ACM System, is rapidly evolving, there is a continuing risk that relative value units assigned, and reimbursement rates set, by CMS may not adequately reflect the value and expense of this technology and associated monitoring services. Further, CMS...
  • acm systems: Although our current iRhythm ACM Systems are comprised of medical devices that have received FDA marketing authorization (510(k) clearance) as well as, with respect to certain devices, regulatory certifications or approvals in the EU, Japan, Switzerland and the UK, we may regularly engage in exploring and...
  • acm system: Because remote cardiac monitoring technology, including the iRhythm ACM System, is rapidly evolving, there is a continuing risk that relative value units assigned, and reimbursement rates set, by CMS may not adequately reflect the value and expense of this technology and associated monitoring services. Further, CMS...
  • irhythm technologies: We are involved in legal proceedings related to securities litigation, patent litigation and other matters and may become involved in other legal proceedings that arise from time to time in the future. For example, as discussed further in Note 8, Commitments and Contingencies, to the Consolidated Financial...
  • code qyx: The CPT codes used to report remote cardiac monitoring services, including those used to report our iRhythm Services, were drafted by the AMA in a manufacturer- and specific technology-agnostic manner. Regulators’ evolving understandings and definitions of certain cardiac monitoring modalities could result in...
  • proposed lcds: Finally, government and commercial payors have and may, in the future, consider healthcare policies and proposals intended to limit or reduce perceived increases in healthcare costs, including those that could significantly affect reimbursement for healthcare products such as our systems and services. These...
  • swiss meddo: As a manufacturer of medical devices, we are subject to extensive regulation and related compliance requirements. Noncompliance and even allegations of noncompliance with these wide-ranging requirements may subject us to high compliance costs to remediate or defend against allegations of noncompliance, as well as...

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

6 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
We previously identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. As previously disclosed, in preparing our consolidated financial statements as of and for the years ended December 31, 2021 and 2020, our management concluded that our disclosure controls and...
In the 10-K filed Feb 20, 2025
To address this material weakness, we took actions designed to improve our internal control over financial reporting and remediate the control deficiencies that led to the material weakness, including hiring additional accounting and finance personnel with an appropriate level of expertise, providing for additional management oversight over financial reporting including through the establishment of a SOX Steering Committee within our internal audit function, and implementing new controls and processes. As of the year ended December 31, 2022, we concluded that our remediation efforts had...
In the 10-K filed Feb 20, 2025
In addition, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies, including those affiliated with the manufacture of certain components of our Zio Monitor System, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providers’ ability to engage in business in the U.S. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China...
In the 10-K filed Feb 20, 2025
Healthcare laws and regulations, and interpretations of the same, change frequently and may change significantly in the future. We may not be able to adapt our operations to address every new regulation or interpretation, and new regulations or interpretations may adversely affect our business. We also cannot assure that a review of our business by courts or regulatory authorities would not result in a determination that adversely affects our revenue and operating results.
In the 10-K filed Feb 20, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IRTC/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.